HDC Health Intelligence Desk | Continuously Updated
Systematic evaluations of telehealth platforms across standardized assessment dimensions. Each analysis examines the platform's clinical protocol design, pricing architecture, pharmacy compliance framework, medication classification accuracy, provider credentialing, and consumer protection infrastructure.
Assessment Dimensions
Telehealth platforms are evaluated across six standardized dimensions:
Clinical Protocol Rigor: How the platform conducts medical evaluations. Assessment covers intake comprehensiveness, contraindication screening, diagnostic appropriateness, and whether the consultation process meets established clinical standards for the condition being treated.
Pricing Architecture: Total cost of engagement — including consultation fees, medication costs, shipping, subscription structures, dose escalation pricing, and the real cost of cancellation. Advertised pricing is compared against actual cost over standard treatment timelines.
Pharmacy Compliance: Licensing verification, compounding pharmacy partnerships, DEA registration where applicable, and state-level regulatory adherence. For platforms dispensing compounded medications, the distinction between compounded and FDA-approved formulations is assessed for accuracy and consumer clarity.
Medication Classification Accuracy: Whether the platform accurately represents what it's prescribing. Compounded medications are not FDA-approved finished drugs — platforms that blur this distinction or fail to make it explicit are flagged.
Provider Credentialing: The qualifications, licensing, and specialty relevance of the clinicians conducting evaluations and prescribing medications through the platform.
Consumer Protection: Refund policies, cancellation procedures, auto-renewal terms, data privacy practices, and dispute resolution mechanisms. These terms are evaluated as written in the platform's terms of service — not as summarized in its marketing.
Published Evaluations
Telehealth platform evaluations will be published as the HDC content library expands. Each evaluation follows the six-dimension framework and includes a structured assessment summary.
Context for Telehealth Consumers
Telehealth platforms typically operate as technology intermediaries connecting patients with licensed providers and partner pharmacies. Understanding this three-party structure — platform, clinician, pharmacy — is essential for evaluating who bears responsibility at each stage of care.
Compounded medications prepared by compounding pharmacies are not FDA-approved finished drugs. The FDA has issued communications regarding risks associated with certain compounded GLP-1 products. Consumers should understand this regulatory distinction before enrolling in programs that prescribe compounded formulations.
The analyses published here evaluate platforms as service offerings. They do not constitute clinical recommendations regarding whether any specific medication or treatment is appropriate for any individual reader. That determination requires direct evaluation by a licensed healthcare provider.
This index is updated as new evaluations are published.